159 related articles for article (PubMed ID: 7614248)
1. Inhibition of HIV-1 by a double transdominant fusion gene.
Aguilar-Cordova E; Chinen J; Donehower LA; Harper JW; Rice AP; Butel JS; Belmont JW
Gene Ther; 1995 May; 2(3):181-6. PubMed ID: 7614248
[TBL] [Abstract][Full Text] [Related]
2. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
Peng H; Callison D; Li P; Burrell C
Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
[TBL] [Abstract][Full Text] [Related]
3. Protection of primary human T cells from HIV infection by Trev: a transdominant fusion gene.
Chinen J; Aguilar-Cordova E; Ng-Tang D; Lewis DE; Belmont JW
Hum Gene Ther; 1997 May; 8(7):861-8. PubMed ID: 9143912
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
Mautino MR; Keiser N; Morgan RA
J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
6. Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells.
Liu J; Woffendin C; Yang ZY; Nabel GJ
Gene Ther; 1994 Jan; 1(1):32-7. PubMed ID: 7584057
[TBL] [Abstract][Full Text] [Related]
7. Tat and rev differentially affect restricted replication of human immunodeficiency virus type 1 in various cells.
Duan L; Oakes JW; Ferraro A; Bagasra O; Pomerantz RJ
Virology; 1994 Mar; 199(2):474-8. PubMed ID: 8122376
[TBL] [Abstract][Full Text] [Related]
8. Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication.
Caputo A; Rossi C; Bozzini R; Betti M; Grossi MP; Barbanti-Brodano G; Balboni PG
Gene Ther; 1997 Apr; 4(4):288-95. PubMed ID: 9176513
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector.
Cara A; Rybak SM; Newton DL; Crowley R; Rottschafer SE; Reitz MS; Gusella GL
Gene Ther; 1998 Jan; 5(1):65-75. PubMed ID: 9536266
[TBL] [Abstract][Full Text] [Related]
10. Exchange of functional domains between Rev proteins of HIV-1 and SIVmac239 results in a dominant negative phenotype.
Berchtold S; Ries J; Hornung U; Aepinus C
Virology; 1994 Oct; 204(1):436-41. PubMed ID: 8091675
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
12. Molecular approaches to inhibit HIV-1 tat expression and functions.
Grossi MP; Caputo A; Zucchini S; Bozzini R; Marconi PC; Manservigi R; Barbanti-Brodano G; Balboni PG
Year Immunol; 1993; 7():199-204. PubMed ID: 8396820
[No Abstract] [Full Text] [Related]
13. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs.
Kashanchi F; Sadaie MR; Brady JN
Virology; 1997 Jan; 227(2):431-8. PubMed ID: 9018142
[TBL] [Abstract][Full Text] [Related]
14. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
15. Infection and replication of Tat- human immunodeficiency viruses: genetic analyses of LTR and tat mutations in primary and long-term human lymphoid cells.
Chang LJ; Zhang C
Virology; 1995 Aug; 211(1):157-69. PubMed ID: 7645208
[TBL] [Abstract][Full Text] [Related]
16. RNA-sequence-mediated gene regulation in HIV-1.
Cullen BR
Infect Agents Dis; 1994; 3(2-3):68-76. PubMed ID: 7812657
[TBL] [Abstract][Full Text] [Related]
17. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.
Fraisier C; Irvine A; Wrighton C; Craig R; Dzierzak E
Gene Ther; 1998 Dec; 5(12):1665-76. PubMed ID: 10023446
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins.
Ulich C; Harrich D; Estes P; Gaynor RB
J Virol; 1996 Jul; 70(7):4871-6. PubMed ID: 8676525
[TBL] [Abstract][Full Text] [Related]
19. Regulation of HIV-1 envelope protein synthesis by Tat and Rev in 293 cells.
Natarajan V; Radjendirane V; Salzman NP
Virology; 1993 Sep; 196(1):122-9. PubMed ID: 8356789
[TBL] [Abstract][Full Text] [Related]
20. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance.
Liem SE; Ramezani A; Li X; Joshi S
Hum Gene Ther; 1993 Oct; 4(5):625-34. PubMed ID: 8280800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]